We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Xceed Grants License for Flow-Thru Chip Technology

By Labmedica staff writers
Posted on 11 Jun 2008
Print article
Xceed Molecular (Toronto, Canada) has granted Gen-Probe (Wellesley, MA, USA) a license to use its Flow-Thru Chip technology for multiplex molecular diagnostics.

Under the terms of the agreement, Gen-Probe will pay up-front licensing and milestone fees to Xceed for non-exclusive access to the technology in specific fields. Gen-Probe also obtained the right to obtain co-exclusive rights (with Xceed) in pre-defined subfields. In addition to continuing royalty payments, the agreement provides that Xceed will supply Gen-Probe with Xceed's custom TipChips, its Ziplex automated gene-expression system, and other Xceed products. Additional terms were not disclosed.

Xceed's 3D Flow-Thru Chip design enables active transport of targets to probes. The chip is made of porous silicon with channels that extend from the upper to the lower surface of the chip. Molecular interactions occur within the three-dimensional matrix of these channels as target solutions pass through. This approach facilitates specific interactions between target molecules and immobilized probes, resulting in hybridization times that are three- to four-times faster than conventional methods.

Gen-Probe's executive vice president and chief scientist, Dan Kacian, Ph.D., M.D., commented, "There are many promising applications for moderate-density arrays in clinical diagnostics and other applications, and we believe that Xceed's technologies in combination with our own technologies will facilitate our entry into these expanding markets.”

Xceed Molecular is a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems. Gen-Probe is a global leader in the development, manufacture, and marketing of rapid, accurate, and cost-effective nucleic acid testing products for diagnosing human diseases and screening donated human blood.


Related Links:
Xceed Molecular
Gen-Probe
Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.